Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

被引：0

作者：

Swords, Ronan T. ^{[1
]}

Savona, Michael R. ^{[2
]}

Maris, Michael B. ^{[3
]}

Erba, Harry P. ^{[4
]}

Berdeja, Jesus G. ^{[5
]}

Foran, James M. ^{[6
]}

Hua, Zhaowei ^{[7
]}

Faessel, Helene M. ^{[7
]}

Dash, Ajeeta B. ^{[7
]}

Sedarati, Farhad ^{[7
]}

Dezube, Bruce J. ^{[7
]}

Medeiros, Bruno C. ^{[8
]}

机构：

[1] Univ Miami Hosp, Sylvester Comprehens Canc Ctr, Miami, FL USA

[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[3] Colorado Blood Canc Inst, Denver, CO USA

[4] Univ Alabama Birmingham, Birmingham, AL USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Mayo Clin, Jacksonville, FL 32224 USA

[7] Takeda Pharmaceut Int Co, Cambridge, MA USA

[8] Stanford Univ, Stanford, MA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 21 条